🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — April 09, 2026

Overnight SEC filings from April 8-9, 2026, reveal a dominant proxy season buildup with 10+ companies (e.g., Piper Sandler, Solid Power, Amazon) scheduling virtual annual meetings around May 20, 2026, urging FOR votes on directors, auditors, and pay amid neutral sentiment but positive highlights like Piper's $1.88B adjusted revenues (+39% NI YoY). Financial results show mixed trends: revenue declines in Beyond Meat (-15.6% YoY to $275M, margins to 2.8%), Resources Connection (-16.6% YoY Q3 to $108M), contrasted by Healthy Extracts (+45% YoY to $4.5M) and EBR Systems (Q1 implants doubled to 41). Biotech shines with IDEAYA-AstraZeneca collaboration on IDE849 for SCLC, while SPAC mergers advance (Abra-New Providence $750M deal, Einride-Legato). Institutional 13F-HR filings (11 funds) confirm heavy tech/ETF allocations (e.g., NVIDIA, Amazon tops), signaling conviction in megacaps. Capital allocation includes News Corp's $1B buyback continuation and Six Flags debt-reducing asset sale. Overall, portfolio-level revenue trends mixed (-16% avg in reporting firms), but positive catalysts in biotech/SPACs outweigh consumer weakness, favoring selective longs pre-market open.

19 high priority 31 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — April 08, 2026

This digest covers one civilian contract totaling $67,726,344 in obligations, with 0/1 defense-related awards, focused on federal construction and infrastructure. The Department of the Interior's Bureau of Reclamation awarded AMES FEDERAL CONTRACTING GROUP LLC a firm fixed price contract for the NGWSP Intake & River Pumping Plant in Farmington, NM, under full and open competition. The highest-conviction signal is neutral (strength 3/10, materiality 2/10) due to the private LLC recipient having no public parent and thus limited direct implications for public market portfolios. No bullish or bearish signals emerge, reflecting the isolated nature of this water supply facilities construction award (NAICS 237110). Key risk is high pricing risk under firm fixed price terms with $0 outlayed to date. Watch total outlayed progress and performance milestones toward the 2028-10-20 end date.

1 total filings
· daily

DHS Homeland Security Contracts — April 08, 2026

DHS awarded $135,428,645 in two civilian contracts during the period, with zero defense-related obligations, split between FEMA's $68.5 million engineering services contract to FOCUS REVISION PARTNERS LLC and ICE's $66.9 million detention services delivery order to THE GEO GROUP, INC. The dominant theme is steady civilian demand in homeland security mitigation and immigration enforcement facilities. Highest-conviction signal is bullish on THE GEO GROUP, INC. (materiality 7/10) for its full-and-open competition win signaling ongoing ICE detention needs. Both contracts carry high fixed-price execution risks, with FOCUS REVISION PARTNERS LLC already at $29 million outlayed toward a potential $118 million ceiling. Key watch item: outlay progress on THE GEO GROUP, INC.'s contract from $0 as it ramps from October 2025.

2 total filings
· daily

VA Healthcare & Services Contracts — April 08, 2026

The three VA Healthcare & Services contracts total $219,450,089 in obligations, entirely civilian with zero defense-related awards, centered on IT and computing services via the Department of Veterans Affairs' Technology Acquisition Center NJ and Veterans Benefits Administration. Salient CRGT, Inc. leads with the highest-materiality $93M obligation (potential $198M with options) for technical application platform services, delivering the strongest bullish signal at 7/10 strength due to full and open competition win and $21.8M early outlays. Greenbrier Government Solutions Inc. adds a solid bullish $61.3M SDVOSB set-aside for software maintenance, with $54.2M already outlayed signaling reliable cash flow. General Dynamics Information Technology's $65.1M award is neutral due to $60.7M subawards eroding prime retention, highlighting a key risk in passthrough exposure. Watch option exercises on Salient CRGT toward the $198M ceiling and remaining outlays across all contracts amid VA budget cycles.

3 total filings
· daily

HHS & Healthcare Contracts Intelligence — April 08, 2026

HHS awarded $300,921,779 across three contracts in the HHS & Healthcare stream, with 0/3 defense-related, focusing on BARDA-funded biotech R&D for biothreat and antibiotic-resistant pathogens. Dominant theme is civilian biothreat preparedness via long-duration BARDA contracts to Shionogi Inc ($119M obligation) and Vedanta Biosciences ($79M obligation), signaling multi-year revenue potential in NAICS 541714 biotechnology R&D. Highest-conviction bullish signals stem from these full-and-open competition awards with options up to $481M for Shionogi and $114M for Vedanta, providing funding visibility amid $70M outlays already for Vedanta. The DLA Troop Support grant ($102M) adds neutral bulk but lacks revenue detail. Key watch item is Shionogi's $0 outlays to date and option exercises across both BARDA contracts, as no funds have flowed yet for the newest award.

3 total filings
· daily

New Federal Contractors — April 08, 2026

These 21 new federal contracts, aggregated at $1,703,423,541 total obligation over April 8, 2026, are entirely civilian with 0/21 defense-related, emphasizing HHS/BARDA biotech R&D, GSA/VA/State/Treasury IT services, and facilities support. Dominant agency themes include HHS ($198M+ across Shionogi and Vedanta), Treasury/IRS ($200M+ via two IBM awards), and VA ($219M+ via Salient CRGT, General Dynamics IT, Greenbrier). Highest-conviction bullish signal is Shionogi Inc's $119M HHS BARDA cost-plus-fixed-fee contract for biothreat antibiotics, with $481M potential over 10 years. Balanced by neutral/dated awards like Smartronix $116M GSA IT (2018-2023, negative outlays) and IBM $110M Treasury terminated in 2025. Key risk/watch: $0 outlays on 8 contracts (e.g., Shionogi, ManTech $77M), signaling near-term execution uncertainty amid CR risk for FY2026 awards.

21 total filings
· daily

Significant Contract Modifications ($10M+) — April 08, 2026

These 21 significant contract modifications totaling $1,703,423,541 in obligations are entirely civilian (0/21 defense-related), highlighting robust federal spending in biotech R&D, IT services, and facilities support outside DOD. Dominant themes include HHS/BARDA biothreat preparedness (Shionogi $119M, Vedanta $79M) and IT modernization across Treasury/IRS (IBM $110M + $90M), VA (Salient CRGT $93M), and GSA (Mantech $77M potential $910M). Highest-conviction bullish signal is Shionogi's $119M BARDA award (up to $482M options) for antibiotics R&D through 2036, signaling multi-year biotech revenue. Key risk is zero outlays on multiple high-value awards (e.g., Shionogi $119M, Mantech $77M, Deloitte $70M), exposing execution delays amid fixed-price structures.

21 total filings
· daily

Contract Deobligations Alert — April 08, 2026

This Contract Deobligations Alert covers 21 civilian contracts totaling $1,703,423,541 in obligations with 0 defense-related awards, highlighting robust civilian agency spending in HHS/BARDA biotech R&D and IT services across GSA, VA, Treasury/IRS, and State Department. Dominant sector themes include biothreat preparedness antibiotics (Shionogi $119M, Vedanta $79M) and multi-year IT modernization (Salient CRGT $93M VA, ManTech $77M GSA USSOUTHCOM cyber, IBM $90M Treasury). Highest-conviction bullish signal is Shionogi Inc's $119M HHS BARDA cost-plus-fixed-fee contract (potential $481M) for late-stage antibiotics R&D through 2036, signaling durable biotech revenue. Balanced by neutral signals on dated contracts like Smartronix's $116M GSA IT (negative -$162k outlays) and IBM's $110M terminated Treasury IT. Key risk is $0 outlays on 8 new/high-potential awards (e.g., ManTech $77M, Deloitte $70M), vulnerable to non-exercise amid CR uncertainty; watch outlay progression and option exercises for revenue conversion.

21 total filings
· daily

Contract Option Exercises — April 08, 2026

These 21 contract option exercises total $1,703,423,541 in obligations, entirely civilian agency awards with zero defense-related contracts, highlighting steady federal spending outside DOD amid a one-day snapshot from April 8, 2026. Dominant themes include HHS/BARDA biotech R&D for biothreat preparedness (e.g., Shionogi $119M, Vedanta $79M) and multi-agency IT modernization/services (IBM $200M+ across two Treasury awards, Salient CRGT $93M VA). Highest-conviction bullish signal is ManTech International's $77M GSA award (up to $910M ceiling) for USSOUTHCOM cyber IT, signaling long-term growth through 2032 despite $0 outlays to date. Key risk is execution uncertainty from $0 outlays on fresh awards like Shionogi and numerous firm-fixed-price structures exposing contractors to cost overruns.

21 total filings
· daily

Federal Professional Services Contracts — April 08, 2026

These four civilian federal professional services contracts total $346,731,554 in obligations, with zero defense-related awards, spanning Department of State, Pension Benefit Guaranty Corporation (PBGC), Department of Transportation (DOT)/Federal Railroad Administration (FRA), and Department of Homeland Security (DHS)/FEMA. The dominant theme is multi-year engineering and administrative support services under NAICS 541330 and related PSCs, with firm-fixed price structures introducing high execution risks. Highest-conviction signal is bullish for SERCO INC's $95.8M PBGC delivery order, where 58% ($55.7M) has already been outlayed shortly after award. Neutral signals dominate for the others due to limited outlays (e.g., $0 for Quality Support, Inc.) and option uncertainties. Key watch item: outlay progress and option exercises across all contracts, given high pricing risks and potential ceilings up to $599M combined.

4 total filings
· daily

All HHS Contracts — April 08, 2026

HHS awarded $300,921,779 across three contracts in this period, all civilian with 0/3 defense-related, dominated by BARDA's biothreat preparedness theme in biotech R&D for antibiotics targeting drug-resistant infections and pathogens. Highest-conviction bullish signals emerge from Shionogi Inc's $119M obligation (potential $481M) and Vedanta Biosciences' $79M obligation ($70M outlayed, potential $114M), providing multi-year revenue visibility in a non-competitive, full-and-open award environment. The neutral $103M grant to DLA Troop Support adds minimal investment signal due to its low materiality and unknown revenue impact. A key risk is Shionogi's $0 outlays to date and uncertain option exercises, warranting close monitoring of funding progress. Overall, this underscores civilian HHS growth in biodefense R&D, differentiating from DOD priorities.

3 total filings
· daily

Mega Contracts Monitor ($100M+) — April 08, 2026

These six civilian mega contracts total $661,042,003 in obligations, with 0/6 defense-related, spanning HHS, GSA, State, Treasury, and NASA. Dominant themes include HHS biothreat preparedness R&D and IT/administrative services, highlighted by Shionogi Inc's $119M BARDA award for antibiotics development. Highest-conviction bullish signal is Shionogi's long-term 10-year structure with $481M potential, alongside Syncom Space Services LLC's $100M NASA facilities support nearing full outlay. Key risk is pervasive $0 outlays across Shionogi ($119M), Quality Support Inc ($113M), and the HHS grant to DLA Troop Support ($103M), signaling execution delays. Watch dated contracts like Smartronix LLC's 2018-2023 GSA IT award with negative -$162k outlays and IBM's terminated Treasury deal.

6 total filings
· daily

High-Value Federal Grants ($5M+) — April 08, 2026

This digest synthesizes 20 high-value federal grants totaling $1,698,888,861 in obligations, all civilian agency awards with 0 defense-related contracts, highlighting steady civilian IT services and biotech R&D spending amid no DOD exposure. Dominant themes include HHS/BARDA biotech for biothreat preparedness ($198M across Shionogi $119M and Vedanta $79M) and multi-agency IT modernization (VA $219M across Salient $93M, GDIT $65M, Greenbrier $61M; Treasury/IRS $201M across two IBM awards $110M+$90M). Highest-conviction bullish signal is Salient CRGT's $93M VA IT delivery order (potential $199M) with $22M already outlayed, signaling strong execution in technical application platforms. Key risk is execution uncertainty from $0 outlays on fresh awards like Shionogi $119M, Mantech $77M (potential $910M for USSOUTHCOM cyber), and Deloitte $70M State IT, vulnerable to delays in funding release.

20 total filings
· daily

General Federal Contracts — April 08, 2026

This digest synthesizes 20 civilian federal contracts totaling $1,698,888,861 in obligations from April 08, 2026, with zero defense-related awards, highlighting steady civilian agency spending in biotech R&D and IT services. Dominant themes include HHS/BARDA biothreat preparedness (e.g., Shionogi Inc's $119M antibiotic development) and VA IT platforms (e.g., Salient CRGT's $93M technical application services), alongside GSA and Treasury IT modernization. Highest-conviction bullish signal is Shionogi Inc's $119M (potential $481M) BARDA cost-plus-fixed-fee contract for multi-year biotech R&D against drug-resistant pathogens, offering durable revenue visibility through 2036. Key risk is execution uncertainty from 10+ contracts with $0 outlays (e.g., ManTech's $77M USSOUTHCOM cyber IT) and dated awards like SMARTRONIX LLC's 2018-2023 GSA IT order showing negative -$162k outlays.

20 total filings
· daily

All NASA Contracts — April 08, 2026

NASA awarded two civilian contracts totaling $104,671,053 in obligations during the April 8, 2026 period, with zero defense-related activity out of two records. The dominant theme is NASA support for space R&D facilities and astrophysics technology maturation at Stennis and Marshall Space Flight Centers. The highest-conviction bullish signal stems from SYNCOM SPACE SERVICES LLC's (Amentum subsidiary) $100,136,373 facilities support contract at Stennis, with $98,511,670 already outlayed indicating strong execution nearing the June 30, 2025 completion. Lockheed Martin Corporation's smaller $4,534,680 TECHMAST contract adds neutral R&D exposure but carries high pricing risk. A key watch item is option exercises on both contracts to reach full ceilings of $102,711,387 for SYNCOM and $4,759,423 for Lockheed amid ongoing outlays.

2 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 08, 2026

Filings reveal selective revenue acceleration in niche operators like ImmuCell (Q1 sales +28.4% YoY to $10.4M, domestic +35.7%) and GameSquare (FY2025 revenue +63% YoY to $45M, Agency segment +119%), offset by persistent net losses (GameSquare $42M improved from $54M; Portsmouth $9.1M from $13.2M) and international softness (ImmuCell -30.2%). IBM stands out with bullish 2025 metrics ($67.5B revenue, $13.2B operating cash, $6.3B shareholder returns including 30th consecutive dividend hike), signaling sustained tech growth into 2026. Proxy materials (IBM, Genco, Portsmouth) show stable governance with flat/mixed compensation and board recommendations against activist proposals. Institutional 13F discloses broad tech exposure (AAPL, AMZN) amid neutral sentiment. Overall mixed sentiment across filings highlights growth pockets in tech-adjacent plays but underscores operational risks and backorder drags; portfolio-level trend of narrowing losses amid revenue beats offers tactical opportunities ahead of May catalysts.

3 high priority 4 medium 7 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 08, 2026

Across the 7 NASDAQ-100 related filings, dominant themes include strategic asset consolidation (Intel's $14.2B JV buyout for full fab control), robust product sales growth in niche biotech (ImmuCell's Q1 2026 +28.4% YoY to $10.4M), institutional portfolio disclosures signaling sustained tech exposure (Community Financial's $568M holdings heavy in Apple/Amazon), proxy solicitations highlighting insider ownership changes (Genco's multiple 2025-2026 Form 4s), SPAC unit liquidity events (Metals Acquisition II separation April 14), speculative crypto ETF launches (Canary PEPE amid high volatility risks), and fund reorganizations (MFS CXE adjournment to April 8). Period-over-period trends show outlier strength in ImmuCell's domestic sales (+35.7% YoY to $9.7M, Tri-Shield +38.5%) contrasting international declines (-30.2%), with no broad margin or revenue compression patterns due to limited financials. Intel's move implies bullish capex commitment amid chip sector rivalry, financed via $6.5B bridge loan (refinance pending market conditions), while PEPE ETF flags extreme speculation risks from 2023's 3.8% supply dump. Portfolio-level implications favor monitoring manufacturing control and growth catalysts, with neutral sentiment dominating (4/7 filings) but high materiality in Intel (9/10) and PEPE (9/10). Actionable now: Favor Intel for supply chain alpha, caution on meme volatility.

3 high priority 4 medium 7 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 08, 2026

Across 50 filings in the USA S&P 500 Financials stream, 13F-HR reports from asset managers (e.g., E Fund, Charis Legacy, Wisconsin Wealth) dominate with neutral sentiment, revealing heavy allocations to tech giants (Apple, Amazon, NVIDIA) and ETFs, signaling institutional conviction in broad market indices amid March 31, 2026 quarter-end. Financials-specific highlights include REIT strength at Kimco Realty (96.4% occupancy, 4% YoY dividend hike to $1.01/share, $248M acquisitions) and Corebridge Financial's transformative all-stock merger with Equitable Holdings targeting $1.5T AUM by YE 2026. Period-over-period trends show revenue growth in outliers like ATRenew (+28.9% YoY to $3B), Grown Rogue (+22% YoY), SmartKem (+750% YoY) but sharp declines in Nurix (-66% YoY revenue, net loss widened to $87M) and cash burn (SmartKem cash -95% to $374k). Capital allocation leans positive with dividends (Ellington $0.08/month, Vistance $10 special), buybacks (Kimco 6.1M shares, News Corp $1B program), and M&A momentum (Corebridge-Equitable, Day One tender at $21.50/share). Proxy-heavy calendar (May 2026 meetings) and merger catalysts signal near-term volatility, favoring patient capital in resilient REITs/financial consolidators over high-burn biotechs.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 08, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning broader sectors), proxy statements dominate (17+ filings) signaling intense AGM season in May 2026, with boards pushing declassification, auditor ratifications, and say-on-pay votes amid stable governance. Earnings reports show mixed period-over-period trends: 9/18 quantifiable filings reported revenue growth averaging +20% YoY (e.g., Delta +13%, RPM +8.9%, ImmuCell +28.4%), but 4 saw sharp declines (Constellation -10%, Mobiquity -95%, Safe & Green dilution risks); margins improved in 4/10 (Richardson +110 bps to 31.9%, RPM EBIT +48.8%) but compressed elsewhere (Constellation Beer -170 bps). Capital allocation leans shareholder-friendly with $255M returns at RPM (+5.2% YoY), $1.6B at Constellation, and steady dividends (Ellington $0.08/share, Constellation +1% to $1.03); M&A active in tuck-ins (PMGC 4 deals, RPM Kalzip) and divestitures (Atkore HDPE sale). Forward guidance mixed: reaffirmations (RPM mid-single digits), raises (Delta low-teens Q2 revenue), cuts/withdrawals (Constellation FY28 outlook gone). Sentiment mixed/neutral overall (28/50), with portfolio-level theme of resilient sales growth masking consumer softness (RPM Consumer -2.4% organic). Implications: Favor dividend payers and M&A consolidators; watch May catalysts for guidance updates amid economic uncertainty.

16 high priority 34 medium 50 total filings